Resmed Stock Price, News & Analysis

ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on September 12, 2022, at 8:45 a.m. ET in New York City. The event will include a live webcast, with a replay available three hours after it concludes, accessible until March 11, 2023. ResMed focuses on innovative solutions for chronic diseases, aiming to improve quality of life and reduce healthcare costs globally.

ResMed's latest research reveals that over 480 million people globally suffer from chronic obstructive pulmonary disease (COPD), a prevalence significantly higher—by 22–126%—than previous estimates. This figure could escalate to 592 million by 2050 if current trends in smoking and air pollution continue. COPD costs the EU approximately €48.4 billion annually, with the U.S. facing over $3 billion in hospitalization costs alone. The study urges immediate action for better screening and treatment, stressing the importance of reducing risk factors associated with COPD.

ResMed reported a 4% increase in year-over-year revenue for Q4 2022, totaling $914.7 million. Operating profit rose 6%, with diluted earnings per share at $1.33. Annual revenue reached $3.6 billion, marking a 12% growth. Despite a 90 bps contraction in gross margin to 56.6%, non-GAAP measures showed resilience with an operating profit increase of 8% for the year. The board declared a 5% increase in dividends to $0.44 per share. The company is optimistic about growth in FY23, aided by new product launches and an upcoming acquisition of MEDIFOX DAN for $1 billion.

ResMed has acquired Leipzig-based mementor as of August 1, 2022, enhancing its digital sleep medicine portfolio in Germany. This strategic move integrates mementor’s somnio, a digital insomnia therapy solution, into ResMed's offerings, filling a significant care gap for patients suffering from insomnia. Somnio, which is the only permanently approved Digital Health Application (DiGA) for insomnia in Germany, is now available via prescription and eligible for reimbursement. This acquisition aims to expand access to effective sleep treatments and leverage ResMed's network for greater adoption.

ResMed (NYSE: RMD) has announced it will release its fourth-quarter fiscal year 2022 financial results on August 11, 2022, after the NYSE closes. Following this, management will host a webcast to discuss the outcomes and other material information. The webcast will be accessible at http://investor.resmed.com. A replay will be available shortly post-webcast, including a phone replay accessible until August 25. ResMed continues to focus on innovative solutions for chronic disease management, aiming to improve quality of life and reduce healthcare costs.

ResMed has announced the promotion of Lucile Blaise to President of Sleep & Respiratory Care, effective July 1, 2022. Blaise, with over 25 years in the medtech industry, previously served as Vice President for Western Europe. She has been influential in establishing payer market access for digital health in France and Belgium and advocates for data privacy and real-world evidence in healthcare. CEO Mick Farrell praised her commitment to patient-centric care and innovative leadership, highlighting her vital role in improving treatments for chronic diseases.

ResMed has announced its acquisition of MEDIFOX DAN, a leader in out-of-hospital software solutions in Germany, for approximately US$1 billion. This acquisition enhances ResMed's position as a significant U.S. provider of SaaS solutions, extending its offerings into outpatient therapy within Germany. MEDIFOX DAN's software solutions are crucial for care providers, and the transaction is expected to be accretive to ResMed's non-GAAP diluted earnings per share. The deal is anticipated to close by the end of December 2022, pending regulatory approvals.

ResMed (NYSE: RMD) CEO Mick Farrell is set to participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 14, 2022, at approximately 1:20 p.m. PDT. This event will take place at the Terranea Resort in Rancho Palos Verdes, California. Interested parties can access a live webcast and a replay of the event via ResMed’s investor relations website, available for 12 hours post-event until June 14, 2023. ResMed focuses on innovative solutions for chronic disease management and aims to improve quality of life while reducing healthcare costs globally.

ResMed (NYSE: RMD) announced that Rob Douglas, its president and COO, will present at the William Blair Growth Stock Conference on June 8, 2022, at 9:20 a.m. CDT. The event will take place at the Loews Chicago Hotel, and investors can access more information and a live webcast through ResMed's investor site. A replay will be available approximately 12 hours after the event until September 6, 2022. ResMed focuses on innovative health solutions for chronic diseases, aiming to improve healthcare quality and reduce costs globally.